329 related articles for article (PubMed ID: 28755680)
1. Capillary leak syndrome in neuromyelitis optica treated with rituximab.
Fuentes Fernandez I; Hernandez-Clares R; Carreón Guarnizo E; Meca Lallana JE
Mult Scler Relat Disord; 2017 Aug; 16():22-23. PubMed ID: 28755680
[TBL] [Abstract][Full Text] [Related]
2. Capillary Leak Syndrome From Rituximab Therapy of Lymphoma.
Vedala K; Desikan SP; McClain C; Jacob D; Desikan R
J Investig Med High Impact Case Rep; 2020; 8():2324709620942372. PubMed ID: 32666835
[TBL] [Abstract][Full Text] [Related]
3. Systemic capillary leak syndrome.
Kawabe S; Saeki T; Yamazaki H; Nagai M; Aoyagi R; Miyamura S
Intern Med; 2002 Mar; 41(3):211-5. PubMed ID: 11929183
[TBL] [Abstract][Full Text] [Related]
4. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
5. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.
Mealy MA; Levy M
J Neuroimmunol; 2015 Oct; 287():29-30. PubMed ID: 26439958
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
8. Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
Berger JR; Neltner J; Smith C; Cambi F
Mult Scler Relat Disord; 2014 Nov; 3(6):728-31. PubMed ID: 25891552
[TBL] [Abstract][Full Text] [Related]
9. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
Pellkofer HL; Suessmair C; Schulze A; Hohlfeld R; Kuempfel T
Mult Scler; 2009 Aug; 15(8):1006-8. PubMed ID: 19667025
[TBL] [Abstract][Full Text] [Related]
10. Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?
Maillart E; Lippi A; Lubetzki C; Louapre C; Papeix C
Mult Scler Relat Disord; 2018 Feb; 20():220-222. PubMed ID: 29433095
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
Annovazzi P; Capobianco M; Moiola L; Patti F; Frau J; Uccelli A; Centonze D; Perini P; Tortorella C; Prosperini L; Lus G; Fuiani A; Falcini M; Martinelli V; Comi G; Ghezzi A
J Neurol; 2016 Sep; 263(9):1727-35. PubMed ID: 27286847
[TBL] [Abstract][Full Text] [Related]
12. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
[TBL] [Abstract][Full Text] [Related]
14. A fatal case of acute progression of generalized edema and simultaneous flash pulmonary edema in a patient with idiopathic systemic capillary leak syndrome: a case report.
Hirosaki Y; Hayashidani S; Ouchi S; Ohshima T; Nakano R; Yamamoto H
J Med Case Rep; 2015 Apr; 9():90. PubMed ID: 25928289
[TBL] [Abstract][Full Text] [Related]
15. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
[TBL] [Abstract][Full Text] [Related]
16. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
Cabre P; Mejdoubi M; Jeannin S; Merle H; Plumelle Y; Cavillon G; Smadja D; Marignier R;
J Neurol; 2018 Apr; 265(4):917-925. PubMed ID: 29455361
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO).
Vaknin-Dembinsky A; Charbit H; Brill L; Abramsky O; Gur-Wahnon D; Ben-Dov IZ; Lavon I
J Neuroinflammation; 2016 Jul; 13(1):179. PubMed ID: 27393339
[TBL] [Abstract][Full Text] [Related]
18. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
[TBL] [Abstract][Full Text] [Related]
19. Rapid exacerbation of neuromyelitis optica after rituximab treatment.
Dai Y; Lu T; Wang Y; Fang L; Li R; Kermode AG; Qiu W
J Clin Neurosci; 2016 Apr; 26():168-70. PubMed ID: 26704780
[TBL] [Abstract][Full Text] [Related]
20. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
